Plecanatide: Completed Phase III enrollment

Synergy completed enrollment of about 1,350 patients in a double-blind, placebo-controlled, U.S. Phase III

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE